// STATE LEGISLATION TRACKER

New Jersey A2001: Establishes pharmacist licensing exemption for certain dialysis-related drugs and devices.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Passed chamber

State: New Jersey
Bill: A2001
Session: 222
Filed: 2026-01-13
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

New Jersey A2001 creates a narrow pharmacist-licensing exemption for manufacturers or wholesale distributors handling certain dialysis-related drugs and devices for home dialysis. Based on the title, subject, and status available, it does not appear to affect compounded peptides, off-label prescribing, peptide telehealth, NP/naturopath scope, 503A/503B compounding, or PDMP rules.

Key Points

No apparent change to compounded peptide access
No apparent change to off-label prescribing rules
No apparent change to telehealth peptide prescribing
No apparent change to NP or naturopath peptide scope
Applies to dialysis-related drugs and devices, not peptides

What to Watch For

Note Watch only if later amendments expand the bill beyond dialysis-related distribution.

Note The bill references FDA-approved dialysis products, not compounded or research peptides.

Note No apparent connection to controlled substances or prescription monitoring from the available bill info.

Where the Bill Stands

The bill passed the Assembly and is now in the Senate Commerce Committee after being received in the Senate.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws